First‐in‐human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection

AIMS: This first‐in‐human clinical trial of P218, a novel dihydrofolate reductase inhibitor antimalarial candidate, assessed safety, tolerability, pharmacokinetics and food effects in healthy subjects. METHODS: The study consisted of two parts. Part A was a double‐blind, randomized, placebo‐controll...

Descripción completa

Detalles Bibliográficos
Autores principales: Chughlay, M. Farouk, Rossignol, Emilie, Donini, Cristina, El Gaaloul, Myriam, Lorch, Ulrike, Coates, Simon, Langdon, Grant, Hammond, Tim, Möhrle, Jörg, Chalon, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256114/
https://www.ncbi.nlm.nih.gov/pubmed/31925817
http://dx.doi.org/10.1111/bcp.14219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256114/
https://www.ncbi.nlm.nih.gov/pubmed/31925817
http://dx.doi.org/10.1111/bcp.14219

Ejemplares similares